

IN THE CLAIMS:

Please cancel claims 1-13 and 19-22 without prejudice.

Please add the following new claims 23-48:

23. A composition for the treatment of asthma, the composition comprising:
 - (a) a leukotriene receptor antagonist;
 - (b) a histamine receptor antagonist; and
 - (c) an adrenergic broncodilator.
24. The composition of claim 23, wherein the adrenergic broncodilator is a beta₂-adrenergic broncodilator.
25. The composition of claim 23, wherein the histamine receptor antagonist is a histamine receptor H₁-receptor antagonist.
26. The composition of claim 25, wherein the histamine receptor antagonist is selected from the group consisting of:
 - (a) cetirizine hydrochloride;
 - (b) loratadine; and
 - (c) fexofenadine.
27. The composition of claim 23, wherein the leukotriene receptor antagonist is selected from the group consisting of:
 - (a) montelukast sodium; and
 - (b) zafirlukast sodium.

28. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is selected from the group consisting of:
cetirizine hydrochloride, loratadine and fexofenadine; and
 - (b) the leukotriene receptor antagonist is selected from the group consisting of:
montelukast sodium and zafirlukast sodium.
29. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is selected from the group consisting of:
cetirizine hydrochloride, loratadine and fexofenadine;
 - (b) the leukotriene receptor antagonist is selected from the group consisting of:
montelukast sodium and zafirlukast sodium; and
 - (c) the adrenergic broncodilator is a beta₂-adrenergic broncodilator.
30. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is cetirizine hydrochloride;
 - (b) the leukotriene receptor antagonist is montelukast sodium; and
 - (b) the adrenergic broncodilator is albuterol sulfate.
31. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is loratadine;
 - (b) the leukotriene receptor antagonist is montelukast sodium; and
 - (b) the adrenergic broncodilator is albuterol sulfate.

32. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is fexofenadine;
 - (b) the leukotriene receptor antagonist is montelukast sodium; and
 - (b) the adrenergic broncodilator is albuterol sulfate.
33. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is cetirizine hydrochloride;
 - (b) the leukotriene receptor antagonist is zafirlukast sodium; and
 - (b) the adrenergic broncodilator is albuterol sulfate.
34. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is loratadine;
 - (b) the leukotriene receptor antagonist is zafirlukast sodium; and
 - (b) the adrenergic broncodilator is albuterol sulfate.
35. The composition of claim 23, wherein
- (a) the histamine receptor antagonist is fexofenadine;
 - (b) the leukotriene receptor antagonist is zafirlukast sodium; and
 - (b) the adrenergic broncodilator is albuterol sulfate.
36. A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 23.

37. The method of claim 36, wherein the amount of the histamine receptor antagonist in the composition is between about 2.5 mg and about 180 mg.
38. The method of claim 36, wherein the amount of the leukotriene receptor antagonist in the composition is between about 4 mg and about 20 mg.
39. The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is between about 4 mg and about 8 mg.
40. The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 2 mg.
41. The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 0.1mg/kg of the patient's body weight.
42. A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 29.
43. A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 30.
44. A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 31.